Filing Flows › Aligos Therapeutics (ALGS) › Q1 2026 › vs Q4 2025
Aligos Therapeutics (ALGS) Q1 2026 vs Q4 2025 (quarter over quarter)
Aligos Therapeutics's revenue rose $2.7M (17×) from $169K in Q4 2025 to $2.8M in Q1 2026.
Aligos Therapeutics, Q1 2026: revenue $2.8M (+810% year over year), operating margin -951.6%, net loss $23.0M, operating cash flow −$23.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.8M | $169K | $2.7M | 17× |
| Other income, net | $4.2M | $2.0M | $2.2M | +114% |
| Net loss | $23.0M | $19.9M | $3.2M | +16% |
| Costs & expenses | $30.1M | $22.0M | $8.1M | +37% |
| Operating costs | $29.8M | $22.0M | $7.8M | +35% |
| Income tax | $317K | $30K | $287K | +957% |
| Research & development | $23.4M | $17.0M | $6.3M | +37% |
| General & admin | $6.4M | $4.9M | $1.5M | +30% |
| Operating cash sources | $24.8M | $23.5M | $1.3M | +6% |
| Depreciation | $346K | $257K | $89K | +35% |
| Share-based compensation | $1.3M | $1.5M | −$144K | -10% |
| Cash used in operations | $23.1M | $21.7M | $1.4M | +6% |
| Net loss absorbed | $23.0M | $19.9M | $3.2M | +16% |
| Working capital & other | $1.7M | $3.6M | −$1.8M | -51% |
Questions
How much did Aligos Therapeutics's revenue grow quarter over quarter in Q1 2026?
Aligos Therapeutics's revenue rose $2.7M (17×) from $169K in Q4 2025 to $2.8M in Q1 2026.